Sonova (OTCMKTS:SONVY) Shares Gap Up – What’s Next?

Sonova Holding (OTCMKTS:SONVY) gapped up before the market opened on Tuesday . The stock had previously closed at $53.33, but opened at $55.44. Sonova shares last traded at $54.94, with a volume of 1,372 shares trading hands.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Royal Bank Of Canada raised shares of Sonova to a “moderate buy” rating in a research report on Tuesday, November 18th. BNP Paribas assumed coverage on shares of Sonova in a research note on Monday, October 20th. They set an “underperform” rating on the stock. Rothschild Redb upgraded shares of Sonova from a “strong sell” rating to a “hold” rating in a report on Monday, October 6th. Finally, Zacks Research cut shares of Sonova from a “hold” rating to a “strong sell” rating in a research note on Tuesday, December 9th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, four have assigned a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold”.

Sonova Price Performance

The stock’s 50-day moving average is $51.41 and its 200-day moving average is $55.03. The company has a current ratio of 1.24, a quick ratio of 0.91 and a debt-to-equity ratio of 0.51.

Sonova Company Profile

Sonova AG (OTCMKTS:SONVY) is a Switzerland-based provider of hearing care solutions, headquartered in Stäfa. The company designs, develops, manufactures and distributes a range of audiological products and related services aimed at improving hearing and communication for people with hearing loss. Its portfolio spans behind-the-ear and in-the-ear hearing instruments, wireless accessories and software solutions that enable connectivity with consumer devices and audiological fittings.

Sonova markets its products under several well-known brands, including Phonak and Unitron for hearing aids, and it is also associated with Advanced Bionics for cochlear implant systems.